Literature DB >> 15560060

The natural history of chronic hepatitis C virus infection.

L B Seeff1.   

Abstract

In conclusion, the natural history of chronic HCV infection has not yet been fully defined. Current data suggest that the process runs an indolent course during the first two decades after initial infection, accounting for modest morbidity and mortality. Serious sequelae are more likely to emerge as the disease process enters the third and fourth decades after infection. These sequelae will presumably be concentrated among those whose liver biopsies display features of cirrhosis, but seem less likely to effect those with liver biopsy evidence of chronic hepatitis alone unless their disease advances to cirrhosis. The frequency of progression from chronic hepatitis to cirrhosis as the disease process enters the third decade remains to be determined. Associated chronic alcoholism appears to be an important additive factor, but other factors that might promote disease progression need to be defined. It seems probable that end-stage liver disease will result in only a proportion of infected individuals. If so, the challenge is to learn how to determine for each individual during the course of their chronic illness what outcome can be expected.

Entities:  

Mesh:

Year:  1997        PMID: 15560060     DOI: 10.1016/s1089-3261(05)70323-8

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  13 in total

1.  Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan.

Authors:  Shih-Chao Kang; Shinn-Jang Hwang; Shiang-Ho Lee; Full-Young Chang; Shou-Dong Lee
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

2.  Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection.

Authors:  C Sagnelli; C Uberti-Foppa; G Pasquale; S De Pascalis; N Coppola; L Albarello; C Doglioni; A Lazzarin; E Sagnelli
Journal:  Infection       Date:  2013-07-10       Impact factor: 3.553

3.  Polymorphisms of some cytokines and chronic hepatitis B and C virus infection.

Authors:  Qiu-Ju Gao; Dian-Wu Liu; Shi-Yong Zhang; Min Jia; Li-Min Wang; Li-Hong Wu; Shu-Yun Wang; Li-Xin Tong
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

Review 4.  Dysmetabolic changes associated with HCV: a distinct syndrome?

Authors:  Amedeo Lonardo; Paola Loria; Nicola Carulli
Journal:  Intern Emerg Med       Date:  2008-02-15       Impact factor: 3.397

Review 5.  Role of iron in hepatic fibrosis: one piece in the puzzle.

Authors:  Marie-A Philippe; Richard-G Ruddell; Grant-A Ramm
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

6.  Experiences of Oxford House Residents Living with the Hepatitis C Virus.

Authors:  Richard Contreras; Leonard A Jason
Journal:  Front Psychol Behav Sci       Date:  2013-04-01

7.  Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry.

Authors:  Seungtaek Kim; Hisashi Ishida; Daisuke Yamane; MinKyung Yi; David C Swinney; Steven Foung; Stanley M Lemon
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

Review 8.  Natural History of Hepatitis C.

Authors:  Shilpa Lingala; Marc G Ghany
Journal:  Gastroenterol Clin North Am       Date:  2015-08-25       Impact factor: 3.806

9.  "They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C.

Authors:  Susan Zickmund; Evelyn Y Ho; Masahiro Masuda; Laura Ippolito; Douglas R LaBrecque
Journal:  J Gen Intern Med       Date:  2003-10       Impact factor: 5.128

10.  High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus.

Authors:  Michael J Wichroski; Jie Fang; Betsy J Eggers; Ronald E Rose; Charles E Mazzucco; Kevin A Pokornowski; Carl J Baldick; Monique N Anthony; Craig J Dowling; Lauren E Barber; John E Leet; Brett R Beno; Samuel W Gerritz; Michele L Agler; Mark I Cockett; Daniel J Tenney
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.